M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
New England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission
* Detailed results from the CENTERSTONE trial show treatment with Xofluza reduced the odds of transmission, or spread of the influenza virus, from an infected person to household members by 32%1
* CENTERSTONE is the first global phase III trial that demonstrates the benefit of an antiviral...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search